MSU
JAZZ icon

Maple Securities USA’s Jazz Pharmaceuticals JAZZ Stock Holding History

Maple Securities USA’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-2,705
Closed -$467K – 270
2015
Q1 		$467K Buy
+2,705
New +$464K 0.04% 119
2014
Q3 		– Sell
-3,491
Closed -$513K – 267
2014
Q2 		$513K Buy
+3,491
New +$484K 0.06% 79

Other funds holding JAZZ

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
WBC
Westpac Banking Corp Sydney, Australia $1.44B AUM 28.5% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Maple Securities USA's JAZZ Position: Q2 2015 in Review

Maple Securities USA sold out of Jazz Pharmaceuticals (JAZZ) in Q2 2015, closing a stake of 2,705 shares — an estimated $467K sold.

Maple Securities USA first reported a position in JAZZ in Q2 2014 and held it in 2 quarters. The position peaked at $513K in Q2 2014. 373 funds tracked by Wall St. Rank hold JAZZ as of Q2 2015.

  • Maple Securities USA reported no remaining Jazz Pharmaceuticals position as of Q2 2015 after selling out during the quarter.
  • Maple Securities USA sold 2,705 Jazz Pharmaceuticals shares in Q2 2015, an estimated $467K.
  • Maple Securities USA first reported a position in Jazz Pharmaceuticals in Q2 2014 and held it in 2 quarters.
  • Maple Securities USA's Jazz Pharmaceuticals position peaked at $513K in Q2 2014.
  • 373 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2015.

Based on Maple Securities USA's 13F filing for Q2 2015, filed 24 Jul 2015.